Phase I study of the combination of quinacrine and erlotinib in patients with locally advanced or metastatic non small cell lung cancer
Investigational New Drugs Oct 06, 2017
Bhateja P, et al. - This Phase I study was designed to examine the safety and assess the maximum tolerated dose of quinacrine in combination with erlotinib in non small cell lung cancer (NSCLC). Findings suggested that combination of quinacrine and erlotinib was well tolerated but had limited efficacy in advanced NSCLC.
Go to Original
Only Doctors with an M3 India account can read this article. Sign up for free or login with your existing account.
4 reasons why Doctors love M3 India
-
Exclusive Write-ups & Webinars by KOLs
-
Daily Quiz by specialty -
Paid Market Research Surveys -
Case discussions, News & Journals' summaries
